Altiratinib
| CAS No. | 1345847-93-9 | Cat. No. | BCP15682 |
| Name | Altiratinib | ||
| Synonyms | DCC-2701;DCC 2701;DCC2701; DP 5164; DP5164; DP-5164; | ||
| Formula | C26H21F3N4O4 | M. Wt | 510.64 |
| Description | Altiratinib, also known as DCC-270, DP-5164, is an oral, selective and highly potent inhibitor of MET, TIE2, VEGFR2 and TRK kinases with potential anticancer activity. DCC-2701 effectively reduces tumor burden in vivo and blocks c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro. Importantly, DCC-2701's anti-proliferative activity was dependent on c-MET activation induced by stromal human fibroblasts and to a lesser extent exogenous HGF. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | Trk Receptor c Met VEGFR Tie2 FLT3 | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.